ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

FRLN Freeline Therapeutics Holdings PLC

6.48
0.00 (0.00%)
06 Jun 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Freeline Therapeutics Holdings PLC FRLN NASDAQ Certificado de Depósito
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.00 0.00% 6.48 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
6.48 6.48
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
24/4/202415:00GLOBEFreeline to Present New Data on its Gaucher and Parkinson’s..
25/2/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
22/2/202415:38EDGAR2Form S-8 POS - Securities to be offered to employees in..
22/2/202415:28EDGAR2Form POS AM - Post-Effective amendments for registration..
20/2/202414:22EDGAR2Form SC 13E3/A - Going private transaction by certain..
20/2/202406:13EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/2/202406:00GLOBEAcquisition of Freeline by Syncona Becomes Effective
12/2/202415:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/2/202411:00GLOBEFreeline Shareholders Approve Acquisition by Syncona
18/1/202415:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/1/202415:17EDGAR2Form SC 13E3/A - Going private transaction by certain..
08/12/202316:21EDGAR2Form SC 13E3 - Going private transaction by certain issuers
01/12/202307:56EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/11/202308:20EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/11/202306:30GLOBESyncona to Acquire Freeline Therapeutics
25/10/202305:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25/10/202301:01GLOBEFreeline Presents Positive New Data from Phase 1/2 GALILEO-1..
18/10/202306:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/10/202306:00GLOBEFreeline to Present New Clinical Data for FLT201 in Gaucher..
06/10/202315:52EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/10/202306:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/10/202306:00GLOBEFreeline Reports Positive Initial Clinical Data from First..
15/8/202306:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/8/202306:00GLOBEFreeline Reports Second Quarter 2023 Financial Results and..
08/8/202306:30GLOBEFreeline Therapeutics to Host Second Quarter 2023 Financial..
31/7/202306:30GLOBEFreeline to Participate in Upcoming Investor Conferences
25/7/202306:30GLOBEFreeline to Host Virtual KOL Event on its Gene Therapy..
26/6/202306:30GLOBEFreeline Announces First Patient Dosed with Its Novel Gene..

Su Consulta Reciente

Delayed Upgrade Clock